Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate (ADC), in Combination with Carboplatin and Bevacizumab: Initial results from a Phase 1b Study in Patients (pts) with Ovarian Cancer
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.